Looking to get ahead in a packed migraine market, Amgen touts head-to-head data for Aimovig

A year after Amgen announced its injectable migraine prevention drug Aimovig proved a better option than the widely used treatment topiramate in a head-to-head study, the pharma company is rolling out the full data. But will it be enough to compete in a packed market, including new oral options?


Click to view original post